Chief Accounting Officer — Anthony Aliquo: The filing announces the internal promotion of an existing Vice President to Chief Accounting Officer, while the CFO retains his title and role.

of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Material Modification to Rights of Security Holders. The information set forth under

Entry into a Material Definitive Agreement. On May 27, 2026, Minerva Neurosciences, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”) with respect to an “at-the market” offering program, pursuant to which the Company may issue and sell, from time to time, shares of its common stock, par value $0.0001 per share (“Common Stock”). The issuance and sale, if any, of shares of the Company’s Common Stock under the Agreement will be effected…

Other Events. As previously announced, the Company is conducting a Phase 3 confirmatory trial, which is referred to as the C19 trial, for its lead product candidate, roluperidone, for the treatment of negative symptoms in patients diagnosed with schizophrenia. The primary efficacy results of the C19 trial will be assessed after 12 weeks of treatment with roluperidone compared to placebo. To support an intended monotherapy indication for roluperidone, patients then enter a relapse assessment p…

of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

President — Geoffrey Race: Mr. Race resigned from his role as President and Director with a settlement agreement.

of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Other Events. At the KOL event, the Company will provide additional details regarding its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophrenia. Subject to ongoing feedback from the U.S. Food and Drug Administration, the trial is currently expected to be initiated, including first patient screened, in the second quarter of 2026. The trial is designed to enroll 380 patients, randomized on a 1:1 basis to receive either placebo or a double-bl…

The filing pertains to an equity incentive plan amendment, not a management change.

Director — Inderjit Kaul, M.D., MPH: Dr. Kaul was appointed as a director and entered into a consulting agreement with the company.

The Series A Preferred Stock are being sold and, upon exercise the securities underlying the Preferred Warrants, will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Regulation D under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 21, 2025, Minerva Neurosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) 80,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”),…

Regulation FD Disclosure. On October 21, 2025, the Company issued a press release announcing the Private Placement, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference. 5

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 12, 2024, on April 10, 2024, Minerva Neurosciences, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 31 consecutive business days, the Company’s minimum Market Value of Listed Securities was below the…

Director and Chair of the Audit Committee — Jeryl Hilleman: Ms. Hilleman is resigning to focus on other opportunities.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2024, Minerva Neurosciences, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS requirement”) for the Company’s common stock had been below the minimum MVLS requirement of $35,000,000 for the last 31 consecut…

Other Events. On February 27, 2024, Minerva Neurosciences, Inc. (the “Company”) issued a press release announcing receipt of a Complete Response Letter from the U.S. Food and Drug Administration in regard to the Company’s New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The offering and sale of the securities will be made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), as a transaction not 1 involving a public offering, and Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The securities will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent regist…

Other Events. On June 28, 2023, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein.

Entry into a Material Definitive Agreement. On June 27, 2023, Minerva Neurosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 1,425,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Com…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2022, on December 1, 2022, Minerva Neurosciences, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities was below…

Director and Chair of the Compensation Committee — William Doyle: Mr. Doyle is resigning to focus on other opportunities.

Chief Executive Officer — Remy Luthringer: Changes to the employment arrangement for the CEO, including severance benefits.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 1, 2022, Minerva Neurosciences, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)…